Similarly, Stojanović et al., 2017, demonstrated in EAE and type 1 diabetes that PoPEx alleviated symptoms of the diseases, which was accompanied by inhibition of immune cell infiltration into pancreatic islets and decreased IL-17 and IFN-γ production in gut-associated lymphoid tissue in vivo and in vitro [44]. This evidence concerns the gene IL17A and type 1 diabetes mellitus.